Robert J Charnigo

Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results

Johnny Mahlangu, José Luis Lamas, Juan Cristóbal Morales et al. · British Journal of Haematology · 2022 · 67 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers

Debra D. Pittman, Patrick C. Hines, David Beidler et al. · Blood · 2020 · 43 citations · Full text

Medicine, Health Sciences, Hematology +11

<scp>PF</scp>‐04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo‐Controlled Study

Robert J Charnigo, David Beidler, Denis Rybin et al. · Clinical and Translational Science · 2018 · 34 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use

Erik Berntorp, David Keeling, Michael Makris et al. · Haemophilia · 2011 · 13 citations

Medicine, Hematology, Pharmacotherapy +10

Assessment of relative bioavailability of two presentations of moroctocog alfa (AF‐CC) in subjects with moderately severe or severe hemophilia A

Frank Shafer, Robert J Charnigo, Anna Plotka et al. · Clinical Pharmacology in Drug Development · 2014 · 13 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +16